

Supplementary Material

Article Title: Innovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012–2024

Authors: John Havlik, M.D., MBA; Sayana Isaac; Caitlin Radovan; Michael J. Ostacher, MD, MPH; David Smith, MD; Taeho Greg Rhee, PhD

DOI Number: 10.4088/JCP.25m16063


LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE


1. [Figure 1](#) Annual Approval of Psychiatric Drugs and Supplemental New Indications 2012-2024, by Measure of Innovation
2. [Table 1](#) Ratings of FDA-Approved Pharmacotherapies for Psychiatric Indications, 2012-2024

DISCLAIMER

This Supplementary Material has been provided by the authors as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Figure 1: Annual approval of psychiatric drugs and supplemental new indications 2012-2024, by measure of innovation.





Note: Data are from WIRB-Copernicus Group Clinical Services CenterWatch, annual biologic approval lists by the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research, annual new molecular entity approval lists by the FDA Center for Drug Evaluation and Research, the Orphan Drug Product designation database, the FDA's expedited development and/or regulatory review programs, the World Health Organization's Model List of Essential Medicines, Prescribe, the Human Drug Advisory Panel, the German Federal Joint Committee, and the French National Authority for Health. *For figures 1B and 1C, 2024 data was not available at time of analysis and so is not displayed.

Supplementary Table 1: Ratings of FDA-approved pharmacotherapies for psychiatric indications, 2012-2024.					
Brand Name	Generic Name	Prescrire (France) Rating	National Authority for Health (France) Rating	Federal Joint Committee (Germany) Rating	Human Drug Advisory Panel (Canada) Rating
Latuda	Lurasidone	Judgement reserved*	High***	Low***	Low***
Fetzima	Levomilnacipran	Judgement reserved*	N/A*	N/A*	Low***
Brintellix/Trintellix	Vortioxetine	Judgement reserved*	Low***	Low***	Low***
Belsomra	Suvorexant	Judgement reserved**	N/A**	N/A**	Low***
Rexulti	Brexipiprazole	Judgement reserved*	N/A*	N/A*	Low***
Addyi	Flibanserin	Judgement reserved**	N/A**	N/A**	Low***
Vraylar	Cariprazine	Clinically not useful***	N/A*	Low***	N/A*
Abilify	Aripiprazole	Judgement reserved**	High***	N/A**	Low***
Nuplazid	Pimavanserin	Judgement reserved**	N/A**	N/A**	N/A**
Vyleesi	Bremelanotide	Judgement reserved**	N/A**	N/A**	N/A*
Spravato	Esketamine	Clinically not useful***	Low***	Low***	N/A*
Zulresso	Brexanolone	Judgement reserved*	N/A*	N/A*	N/A*
Caplyta	Lumateperone	Judgement reserved**	N/A**	N/A**	N/A**
Dayvigo	Lemborexant	Judgement reserved**	N/A**	N/A**	Low***
Azstarys	Serdexmethylphenidate-dexmethylphenidate	Judgement reserved**	N/A**	N/A**	N/A**
Qelbree	Viloxazine	Judgement reserved*	N/A*	N/A*	N/A*
Lybalvi	Olanzapine-samidorphan	Judgement reserved**	N/A**	N/A**	N/A*
Quviviq	Daridorexant	Clinically not useful***	Low***	Low***	N/A*
Auvelity	Dextromethorphan & Bupropion	Judgement reserved**	N/A**	N/A*	N/A*
Zurzuvae	Zuranolone	Judgement reserved**	N/A**	N/A**	N/A**
Exxua	Gepirone	Judgement reserved**	N/A**	N/A**	N/A**
Cobenfy	Xanomeline & Trospium Chloride	Judgement reserved**	N/A**	N/A**	N/A**
Judgement Reserved or N/A - *		No rating was found, but the drug was approved in the provided country.			
Judgement Reserved or N/A - **		No rating was found, and the drug was not approved in the provided country.			
Clinically not useful/Clinically useful or Low/High - ***		A rating was found, and the drug was approved in the provided country.			